Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study

NCT05310383 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05310383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05310383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Unknown status
Start date
March 27, 2022
Completion date
March 27, 2024
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-programmed cell death receptor 1, immune checkpoint inhibitors, immunotherapy, metastatic cervical carcinoma, objective response rate, persistent cervical carcinoma, radiotherapy, recurrent cervical carcinoma, survival outcomes, tislelizumab